Parameter | n | Baseline (25 min) | KV7 Modulation (20 min) | Reperfusion | Two-Way ANOVA | ||
---|---|---|---|---|---|---|---|
+2 min | +30 min | +120 min | |||||
LVDP (mm Hg) | |||||||
DMSO | 6 | 158 ± 8 | 157 ± 9 | 4 ± 2 | 20 ± 5 | 24 ± 5 | |
IPC | 7 | 155 ± 6 | 151 ± 9 | 6 ± 1 | 58 ± 7‡ | 40 ± 4 | 0.004 |
XE991 | 7 | 150 ± 3 | 149 ± 5 | 3 ± 1 | 39 ± 7 | 49 ± 6 | 0.025 |
XE991 plus IPC | 8 | 156 ± 9 | 157 ± 8 | 8 ± 2 | 90 ± 3‡ | 75 ± 4‡ | <0.001 |
Linopirdine | 8 | 144 ± 4 | 163 ± 3 | 2 ± 1 | 37 ± 5 | 44 ± 3 | 0.135 |
Linopirdine plus IPC | 8 | 145 ± 11 | 156 ± 13 | 4 ± 1 | 69 ± 7‡ | 57 ± 6‡ | <0.001 |
Flupirtine | 7 | 151 ± 12 | 166 ± 13 | 4 ± 2 | 24 ± 5 | 19 ± 5 | >0.99 |
Flupirtine plus IPC | 4 | 141 ± 5 | 143 ± 4 | 2 ± 0 | 33 ± 11 | 17 ± 3 | >0.99 |
LVEDP (mm Hg) | |||||||
DMSO | 6 | 5 ± 2 | 5 ± 2 | 91 ± 6 | 50 ± 6 | 38 ± 7 | |
IPC | 7 | 6 ± 1 | 6 ± 1 | 81 ± 10 | 28 ± 5† | 28 ± 5 | 0.513 |
XE991 | 7 | 2 ± 3 | 3 ± 1 | 77 ± 6 | 31 ± 3† | 17 ± 2† | 0.179 |
XE991 plus IPC | 8 | 7 ± 1 | 6 ± 2 | 48 ± 6‡ | 9 ± 4‡ | 15 ± 6† | <0.001 |
Linopirdine | 8 | 1 ± 1 | 0 ± 1 | 78 ± 3 | 28 ± 3† | 16 ± 3† | 0.064 |
Linopirdine plus IPC | 8 | 4 ± 2 | 5 ± 2 | 68 ± 10† | 19 ± 7‡ | 17 ± 6† | 0.010 |
Flupirtine | 7 | 8 ± 1 | 9 ± 1 | 84 ± 8 | 54 ± 6 | 40 ± 8 | >0.99 |
Flupirtine plus IPC | 4 | 0 ± 1 | 0 ± 1 | 73 ± 4 | 29 ± 6* | 23 ± 2 | |
Heart rate (beats/min) | |||||||
DMSO | 6 | 268 ± 13 | 282 ± 14 | 253 ± 29 | 290 ± 23 | 248 ± 10 | 0,435 |
IPC | 7 | 250 ± 15 | 259 ± 16 | 230 ± 18 | 265 ± 6 | 243 ± 15 | >0.99 |
XE991 | 7 | 258 ± 17 | 240 ± 16 | 199 ± 24 | 240 ± 10 | 218 ± 9 | 0.399 |
XE991 plus IPC | 8 | 251 ± 11 | 207 ± 9* | 204 ± 19 | 242 ± 10 | 215 ± 17 | 0.237 |
Linopirdine | 8 | 294 ± 16 | 269 ± 11 | 223 ± 15 | 310 ± 14 | 234 ± 7 | >0.99 |
Linopirdine plus IPC | 8 | 282 ± 8 | 261 ± 11 | 216 ± 18 | 259 ± 13 | 253 ± 8 | >0.99 |
Flupirtine | 7 | 275 ± 12 | 256 ± 11 | 198 ± 33 | 217 ± 9* | 205 ± 18 | 0.732 |
Flupirtine plus IPC | 4 | 262 ± 13 | 276 ± 14 | 189 ± 37 | 243 ± 8 | 219 ± 15 | 0.536 |
CF (ml/min) | |||||||
DMSO | 6 | 15.9 ± 0.6 | 16.0 ± 0.4 | 12.4 ± 0.7 | 13.5 ± 0.7 | 8.3 ± 0.7 | |
IPC | 7 | 15.4 ± 0.5 | 15.5 ± 0.7 | 13.0 ± 0.6 | 14.3 ± 1.1 | 9.9 ± 1.0 | >0.99 |
XE991 | 7 | 15.1 ± 0.7 | 12.4 ± 0.8* | 12.1 ± 0.8 | 12.5 ± 0.9 | 7.6 ± 0.5 | >0.99 |
XE991 plus IPC | 8 | 12.5 ± 0.6* | 9.2 ± 0.6‡ | 12.4 ± 0.5 | 11.7 ± 0.7 | 6.9 ± 0.4 | 0.944 |
Linopirdine | 8 | 16.0 ± 0.7 | 16.0 ± 0.8 | 12.6 ± 0.7 | 14.7 ± 0.7 | 10.2 ± 0.6 | >0.99 |
Linopirdine plus IPC | 8 | 14.0 ± 0.7 | 13.9 ± 1.1 | 12.7 ± 0.9 | 13.0 ± 0.9 | 9.4 ± 0.8 | >0.99 |
Flupirtine | 7 | 15.0 ± 0.9 | 15.0 ± 0.7 | 11.2 ± 0.5 | 11.9 ± 0.6 | 7.7 ± 0.8 | >0.99 |
Flupirtine plus IPC | 4 | 14.0 ± 1.8 | 12.4 ± 4.2 | 11.7 ± 1.8 | 12.2 ± 1.6 | 6.6 ± 0.8 | >0.99 |
CF, coronary flow rate; LVDP, left ventricular developed pressure; LVEDP, left ventricular end diastolic pressure.
↵* P < 0.05 versus DMSO; †P < 0.01 versus DMSO; ‡P < 0.001 versus DMSO.